Cargando…
Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody–drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. F...
Autores principales: | Reinert, Jochim, Beitzen-Heineke, Antonia, Wethmar, Klaus, Stelljes, Matthias, Fiedler, Walter, Schwartz, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510963/ https://www.ncbi.nlm.nih.gov/pubmed/34331563 http://dx.doi.org/10.1007/s00277-021-04601-0 |
Ejemplares similares
-
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
por: Fingrut, Warren, et al.
Publicado: (2020) -
Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019) -
Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
por: Wullenkord, Ramona, et al.
Publicado: (2020) -
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018) -
CD22(low)/Bcl-2(high) expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia
por: Wintering, Astrid, et al.
Publicado: (2022)